Investor Announcements - 2013

Interim results

16^th Sep 2013

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2013.

Final results for the year ended 31 December 2012

18^th Mar 2013

Final results for the year ended 31 December 2012.

Establishment of EKF Molecular Diagnostics & Acquisition of 360 Genomics Limited

4^th Mar 2013

EKF Diagnostics announces that it has established a new subsidiary, EKF Molecular Diagnostics Limited (“EKF Molecular”), to focus on molecular and companion diagnostics.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF launches FDA CLIA-waived β-ketone and glucose POC analyzer to U.S. market

New handheld STAT-Site WB ensures reliable and efficient analysis from whole blood

Supporting reduction of anemia in developing regions in South America

Symposium highlights successful use of EKF’s Hemo Control hemoglobin analyzer in extreme environmental conditions

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities